20th week of 2022 patent applcation highlights part 10 |
Patent application number | Title | Published |
20220152031 | PYRIDAZINONES AND METHODS OF USE THEREOF - Disclosed are therapeutic methods, e.g., of treating kidney diseases, using compounds of Formula (A) in combination with a second therapeutic agent. | 2022-05-19 |
20220152033 | COMPOSITIONS AND METHODS FOR DEEP DERMAL DRUG DELIVERY - Pharmaceutical compositions for the topical administration of a drug to the pilosebaceous unit and methods for administering the same. As disclosed herein, the inventors of the present invention have made the surprising discovery that pharmaceutical compositions comprising small particles of an active pharmaceutical ingredient and a silicone, such as dimethicone or cyclomethicone, can be administered to the pilosebaceous unit. The pharmaceutical composition can comprise SHR0302 or spironolactone as an active pharmaceutical ingredient. | 2022-05-19 |
20220152034 | PREVENTION AND/OR TREATMENT OF CNS DISORDERS - Adenosine receptor (e.g., A2A and/or A1 receptor) antagonist compounds and compositions including said compounds are disclosed. The present disclosure also provides methods of using said compounds and compositions for modulating (e.g., inhibiting or antagonizing) A2A and/or A1 receptor in a biological system. The compounds and compositions find use in various therapeutic applications including the treatment of central nervous system or neurodegenerative diseases, such as Parkinson's disease. The compounds and compositions may also find use in various therapeutic applications including the treatment of cancer and in immuno-oncology. | 2022-05-19 |
20220152035 | Cancer Treatment Targeted to Tumor Adaptive Responses to Protein Synthesis Stress - In cancers such as prostate cancer, the combination of PTEN loss and activation of Myc activates an adaptive stress response that enables tumor cells to escape the stress of massively upregulated protein synthesis. This pro-survival response is mediated by the PERK-phosphorylated eIF2α axis of the UPR adaptive response. Agents that disrupt PERK-eIF2α pathways disrupt the adaptive response and lead to cancer cell death from uncontrolled growth. For example, ISRIB and derivatives may be employed as therapeutic agents to disrupt PERK-mediated adaptive mechanisms. Additionally PTEN loss and activation of Myc provides a diagnostic marker that enables better prognosis and the selection of amenable treatments. | 2022-05-19 |
20220152036 | COMPOUNDS FOR USES IN PHARMACOLOGICAL INDUCTION OF HBF FOR TREATMENT OF SICKLE CELL DISEASE AND -THALASSEMIA - Provided herein are compounds of Formula (I). The compounds described herein are useful in treating a disease associated with the expression of endogenous embryonic/fetal globin (e.g., γ globin) in erythrocytes (e.g., treating β-thalassemia and/or sickle cell disease through at least the induction of the globin gene expression in erythrocytes), and/or anemia (β-thalassemia and/or sickle cell anemia). The compounds described herein are useful in treating, delaying, and/or preventing the adverse effects of β-thalassemia and/or sickle cell disease, inducing γ globin production, and/or inducing the expression of embryonic/fetal globin genes in a subject, cell, tissue, or biological sample. Also provided in the present disclosure are pharmaceutical compositions, kits, and methods of using the compounds for inducing γ globin production described herein and for treating any of the target diseases described herein. | 2022-05-19 |
20220152037 | USE OF GABAA RECEPTOR MODULATORS FOR TREATMENT OF PAIN - Disclosed herein are GABA | 2022-05-19 |
20220152038 | 3, 7-DIAMINO-10H-PHENOTHIAZINE SALTS AND THEIR USE - Described are methods of prepraing reduced 3,7-diamino-10H-phenothiazine (DAPTZ) compounds of formula: | 2022-05-19 |
20220152039 | TRANSDERMAL DELIVERY OF DICLOFENAC, CARBAMAZEPINE AND BENZYDAMINE - The invention discloses solutions of diclofenac, carbamazepine and benzydamine, at therapeutically desirable concentrations and the solutions stable for extended periods of time at room temperature. | 2022-05-19 |
20220152040 | ANTIPSYCHOTIC AND USE THEREOF - An object of the present invention is to provide a novel therapeutic agent for a mental disorder with abnormal neurodevelopment as a pathological condition. The present invention provides an antipsychotic drug containing a Rho kinase inhibitor as an active ingredient. The antipsychotic drug can be used, for example, in the treatment of schizophrenia, autism spectrum disorder, bipolar disorder, or depression. | 2022-05-19 |
20220152041 | CALMODULIN INHIBITORS FOR THE TREATMENT OF RIBOSOMAL DISORDERS AND RIBOSOMAPATHIES - The present invention relates generally to methods, compositions and kits for treatment of ribosomal disorders and ribosomopathy, e.g. Diamond Blackfan anemia (DBA). In some embodiments, the invention relates to methods for the use of calmodulin inhibitors and calcium channel blockers for treatment of ribosomal disorders and ribosomopathy, e.g. Diamond Blackfan anemia (DBA). | 2022-05-19 |
20220152042 | DIETARY SUPPLEMENT - A method of forming a dietary supplement can include steps of creating a composition of matter comprising tianeptine, sakae naa, and optionally, at least one of kava, CDP Choline, and Alpha GPC; and providing the composition of matter in a liquid or solid form. The ingredient of tianeptine can be tianeptine sodium, tianeptine free acid, or both. Providing the composition of matter can include filling a container with the composition of matter. | 2022-05-19 |
20220152043 | DIETARY SUPPLEMENT - A method of forming a dietary supplement can include steps of creating a composition of matter comprising tianeptine, kava, and optionally, at least one of CDP Choline, and Alpha GPC; and providing the composition of matter in a liquid or solid form. The ingredient of tianeptine can be tianeptine sodium, tianeptine free acid, or both. Providing the composition of matter can include filling a container with the composition of matter. | 2022-05-19 |
20220152044 | TREATMENT OF INFLAMMATORY DISEASES OF THE CENTRAL NERVOUS SYSTEM - The present invention relates to the use of flumazenil for the treatment of inflammatory conditions of the central nervous system, such as migraine, headache and multiple sclerosis, anxiety, PTSD, psychosis, depression, and cessation of addictive behaviours. The active may be administered in the form of an implant. The present invention also relates to the use of flumazenil, naltrexone, and optionally buprenorphine in order to reduce symptoms associated with withdrawal of drugs of dependence or addictive behaviours. | 2022-05-19 |
20220152045 | DOSING REGIMEN OF SEDATIVE - By intravenously administering a sedative comprising methyl 3-[(4S)-8-bromo-1-methyl-6-(2-pyridinyl)-4H-imidazo[1,2-a][1,4]benzodiazepin-4-yl]propanoate or a salt thereof to a patient by a dosing regimen including a two-step process disclosed in the present invention, general anesthesia can be safely and promptly induced and maintained. | 2022-05-19 |
20220152046 | APPLICATIONS FOR ESTRADIOL IN PREPARING ANTI-SMALL CELL LUNG CANCER AND/OR OVARIAN CANCER AND/OR OSTEOSARCOMA PRODUCTS - This invention discloses uses for estradiol in preparing anti-small cell lung cancer and/or ovarian cancer and/or osteosarcoma products. This invention provides uses for estradiol in preparing anti-small cell lung cancer and/or ovarian cancer and/or osteosarcoma products. From carrying out cancer drug repositioning for the FDA- and CFDA-approved drug estradiol, experiments for this invention show, based on screening of non-anti-cancer drugs for various cancer cell lines (tissue types) and mutation sites, that estradiol has a new use as an anti-small cell lung cancer and/or ovarian cancer and/or osteosarcoma medication, thus achieving a new purpose for an old drug. | 2022-05-19 |
20220152047 | COMPOSITIONS FOR THE TREATMENT OF CHRONIC VULVAL AND PERINEAL PAIN AND SYMPTOMS AND CONDITIONS ASSOCIATED THEREWITH - Provides herein are compositions for the treatment of chronic vulval or perineal pain, and of symptoms or conditions associated therewith, comprising an estrogen, optionally estriol, and a tricyclic antidepressant, optionally amitriptyline, formulated for topical, transdermal or transmucosal administration. Also provided are methods for the production of said compositions and to uses thereof in the treatment of chronic vulval or perineal pain, and of symptoms or conditions associated therewith. | 2022-05-19 |
20220152048 | Botanical Extracts and Compounds from Castanea Plants and Methods of Use - This disclosure relates to extracts from chestnut plants and compositions comprising compounds contained therein. In certain embodiments, the extracts are derived from the leaves of a | 2022-05-19 |
20220152049 | METHODS OF TESTOSTERONE THERAPY - Methods and systems for preventing or reducing side effects of testosterone replacement therapy (TRT) by administering a testosterone formulation multiple times per day are disclosed. The methods of the present invention enable men who cannot tolerate previous TRT regimens, e.g. because they wish to attempt to conceive or are at risk of developing cardiovascular side effects, to receive TRT treatment. | 2022-05-19 |
20220152050 | METHODS OF TREATING EPILEPSY OR STATUS EPILEPTICUS - Described herein are methods of treating epilepsy or status epilepticus, e.g., convulsive status epilepticus, e.g., early status epilepticus, established status epilepticus, refractory status epilepticus, super-refractory status epilepticus, e.g., super-refractory generalized status epilepticus; non-convulsive status epilepticus, e.g., generalized status epilepticus, complex partial status epilepticus; generalized periodic epileptiform discharges; periodic lateralized epileptiform discharges; a seizure, e.g., acute repetitive seizures, cluster seizures, the method comprising administering to the subject a neuroactive steroid. | 2022-05-19 |
20220152051 | APPLICATION OF GLYCOCHOLIC ACID IN PREPARATION OF ANTITUMOR DRUGS - The present invention relates to a use of a chemical drug in the field of medicine, and relates in particular to an application of glycocholic acid in the preparation of anti-tumor drugs. Provided by the present invention is a new application field for glycocholic acid, wherein glycocholic acid can be used in the preparation of anti-tumor drugs; the main applicable tumors comprise breast cancer, ovarian cancer, endometrial cancer, or a combination thereof; and glycocholic acid is used as an effective active ingredient in anti-tumor drugs. The present invention is beneficial in developing new anti-tumor drugs. | 2022-05-19 |
20220152052 | METHODS AND COMPOSITIONS FOR TREATING VARIOUS DISORDERS - Provided herein are methods and compositions for treating at least one symptom of ALS, slowing ALS disease progression, or reducing the deterioration of one or more bodily functions affected by ALS in a subject. The methods can include administering to the subject a bile acid or a pharmaceutically acceptable salt thereof and a phenylbutyrate compound. | 2022-05-19 |
20220152053 | METHODS AND COMPOSITIONS FOR TREATING VARIOUS DISORDERS - Provided herein are methods and compositions for treating at least one symptom of ALS, slowing ALS disease progression, or reducing the deterioration of one or more bodily functions affected by ALS in a subject. The methods can include administering to the subject a bile acid or a pharmaceutically acceptable salt thereof and a phenylbutyrate compound. | 2022-05-19 |
20220152054 | METHODS AND COMPOSITIONS FOR TREATING VARIOUS DISORDERS - Provided herein are methods and compositions for treating at least one symptom of ALS, slowing ALS disease progression, or reducing the deterioration of one or more bodily functions affected by ALS in a subject. The methods can include administering to the subject a bile acid or a pharmaceutically acceptable salt thereof and a phenylbutyrate compound. | 2022-05-19 |
20220152055 | METHODS AND COMPOSITIONS FOR TREATING VARIOUS DISORDERS - Provided herein are methods and compositions for treating at least one symptom of ALS, slowing ALS disease progression, or reducing the deterioration of one or more bodily functions affected by ALS in a subject. The methods can include administering to the subject a bile acid or a pharmaceutically acceptable salt thereof and a phenylbutyrate compound. | 2022-05-19 |
20220152056 | METHODS AND COMPOSITIONS FOR TREATING VARIOUS DISORDERS - Provided herein are methods and compositions for treating at least one symptom of ALS, slowing ALS disease progression, or reducing the deterioration of one or more bodily functions affected by ALS in a subject. The methods can include administering to the subject a bile acid or a pharmaceutically acceptable salt thereof and a phenylbutyrate compound. | 2022-05-19 |
20220152057 | METHODS AND COMPOSITIONS FOR TREATING VARIOUS DISORDERS - Provided herein are methods and compositions for treating at least one symptom of ALS, slowing ALS disease progression, or reducing the deterioration of one or more bodily functions affected by ALS in a subject. The methods can include administering to the subject a bile acid or a pharmaceutically acceptable salt thereof and a phenylbutyrate compound. | 2022-05-19 |
20220152058 | METHODS AND COMPOSITIONS FOR TREATING VARIOUS DISORDERS - Provided herein are methods and compositions for treating at least one symptom of ALS, slowing ALS disease progression, or reducing the deterioration of one or more bodily functions affected by ALS in a subject. The methods can include administering to the subject a bile acid or a pharmaceutically acceptable salt thereof and a phenylbutyrate compound. | 2022-05-19 |
20220152059 | METHODS AND COMPOSITIONS FOR TREATING VARIOUS DISORDERS - Provided herein are methods and compositions for treating at least one symptom of ALS, slowing ALS disease progression, or reducing the deterioration of one or more bodily functions affected by ALS in a subject. The methods can include administering to the subject a bile acid or a pharmaceutically acceptable salt thereof and a phenylbutyrate compound. | 2022-05-19 |
20220152060 | PHYTOECDYSONES AND THE DERIVATIVES THEREOF FOR USE IN THE TREATMENT OF IMPAIRED LUNG FUNCTION - Disclosed are phytoecdysones and the derivatives thereof, intended for use in the treatment of impaired lung function in mammals, in particular in the context of a neuromuscular disease and more particularly when the impaired lung function is linked to a deterioration of the mechanical properties of the lung tissue. | 2022-05-19 |
20220152061 | COMPOSITIONS AND METHODS FOR DEEP DERMAL DRUG DELIVERY - Pharmaceutical compositions for the topical administration of a drug to the pilosebaceous unit and methods for administering the same. As disclosed herein, the inventors of the present invention have made the surprising discovery that pharmaceutical compositions comprising small particles of an active pharmaceutical ingredient can be administered to the pilosebaceous unit. The pharmaceutical composition can comprise SHR0302 or spironolactone as an active pharmaceutical ingredient. | 2022-05-19 |
20220152062 | USE OF CAROTENOIDS IN THE TREATMENT OF SENESCENCE-RELATED DISEASES - The invention relates to a combination comprising a carotenoid, a carotenoid metabolite, a carotenoid derivative, analogue or an ester or salt thereof and a second component selected from the group consisting of an inhibitor of one or more members of the BCL-2 anti-apoptotic protein family, an activator of pro-apoptotic BCL-2 family members, a senolytic agent and a senomorphic agent. The invention also relates to a food, a cosmeceutical, a nutraceutical, a cosmetic or pharmaceutical composition comprising the combination of the invention and its use in a cosmetic method and it medical uses. | 2022-05-19 |
20220152063 | NITRIC OXIDE-RELEASING ANTIBACTERIAL COMPOUNDS, FORMULATIONS, AND METHODS PERTAINING THERETO - Several embodiments of NO releasing compounds are disclosed. In some embodiments, the structures are covalently modified to store and release nitric oxide. Some embodiments pertain to methods of making and use of these structures. The compounds may be tailored to release nitric oxide in a controlled manner and can be useful, for example, for treating or preventing microbial infections, or reducing the microbial load of a microbial infection. | 2022-05-19 |
20220152064 | BENZOAZEPINE COMPOUND-CONTAINING PHARMACEUTICAL COMPOSITION - A means for reducing side effects of tolvaptan is provided. Specifically, the means provides a pharmaceutical composition comprising a compound represented by Formula (1): | 2022-05-19 |
20220152065 | METHOD OF BLOCKING OR AMELIORATING CYTOKINE RELEASE SYNDROME - Disclosed herein are embodiments of a method for treating or preventing cytokine release syndrome (CRS). In certain embodiments, the method comprises administering a compound, or a salt, solvate, prodrug or pharmaceutical composition thereof, to a subject experiencing, or at risk of developing, CRS. The compound may be a Syk inhibitor, and/or may have a structure according to Formula I. And the method may comprise administering the compound to a subject who is has received, is currently receiving, and/or will be receiving a cell therapy. | 2022-05-19 |
20220152066 | COMPOSITION WITH NON-DIGESTIBLE OLIGOSACCHARIDES FOR ATTENUATING NASAL EPITHELIAL INFLAMMATION - The present invention relates to the use of non-digestible oligosaccharides for the direct attenuation of nasal epithelial inflammation, in particular for non-allergic rhinitis, in particular for use in infants. | 2022-05-19 |
20220152067 | Cancer Immunotherapy Adjuvant - The present invention relates to a cancer immunotherapy adjuvant, wherein the adjuvant, when administered in combination with a cancer immunotherapy agent, activates the function of immune factors without causing in vivo side effects, to exhibit the effect of enhancing the kit for anticancer effect of the cancer immunotherapy agent, and thus can be effectively used as a cancer immunotherapy adjuvant. | 2022-05-19 |
20220152068 | DRUG DELIVERY CARRIER UTILIZING PROPERTY OF D-ALLOSE BEING UPTAKEN BY CANCER CELL, DRUG DELIVERY METHOD, AND COMPOSITION FOR TREATING RENAL CELL CARCINOMA - To provide a composition for the treatment of renal cell carcinoma and a composition or a method for enhancing the uptake of a drug into renal cell carcinoma cells. Provided are a D-allose-containing composition for the treatment of renal cell carcinoma, and a D-allose-containing composition or method for enhancing the uptake of a drug into renal cell carcinoma cells. The composition is a pharmaceutical composition to be administered in an effective amount to patients requiring the treatment of renal cell carcinoma in humans or animals other than humans. | 2022-05-19 |
20220152069 | COMPOUNDS AND PHARMACEUTICAL USES THEREOF - A method of treating coronavirus infection, comprising administering to a subject in need thereof an effective amount of a composition, wherein the composition comprises one or more compounds of Formula (I): | 2022-05-19 |
20220152070 | PHARMACEUTICAL COMPOSITION AND METHOD FOR NEOANGIOGENESIS/REVASCULARIZATION USEFUL IN TREATING ISCHEMIC HEART DISEASE - A pharmaceutical composition and a method of treating ischemic heart diseases by growing new blood vessels that supply oxygen and nutrients to infarcted heart tissues throughout the entire infarct zone and for preventing cardiomyocyte apoptosis in ischemic events. The pharmaceutical composition contains and active ingredient compound with a backbone structure of formula (I). | 2022-05-19 |
20220152071 | MARKERS OF EFFICACY OF TOPOISOMERASE POISONS - Disclosed are methods, components, and systems for diagnosing, prognosing, and treating a cell proliferative disease or disorder such as cancer. The methods, components, and systems relate to identifying markers that may be utilized to diagnose and/or prognose a subject and optionally treat the diagnosed and/or prognosed subject by administering a topoisomerase poison to the subject based on the marker having been identified. Markers identified in the methods may include ribosomal subunit proteins and genes encoding ribosomal subunit proteins. Based on the marker being identified in the subject, the subject may be identified as having responsiveness to a topoisomerase poison, such as etoposide and/or doxombicin. As such, the subject may be treated by administering the topoisomerase poison to treat the cell proliferative disease or disorder after the marker has been identified. | 2022-05-19 |
20220152072 | Selective Inhibitors Of Protein Arginine Methyltransferase 5 (PRMT5) - The disclosure is directed to methods of treating disease using compounds of Formula (I). | 2022-05-19 |
20220152073 | Selective Inhibitors Of Protein Arginine Methyltransferase 5 (PRMT5) - The disclosure is directed to methods of treatment using compounds of Formula (I). | 2022-05-19 |
20220152074 | TREATMENT OF HEMATOLOGICAL DISORDERS - The invention relates to compositions and methods for treating patients with hematological proliferative disorders with CPX-351, a liposomal composition of daunorubicin and cytarabine, and venetoclax. | 2022-05-19 |
20220152075 | COMPOSITIONS CONTAINING DECITABINE, 5AZACYTIDINE AND TETRAHYDROURIDINE AND USES THEREOF - Compositions comprising decitabine and tetrahydrouridine or 5-azacytidine and tetrahydrouridine for the treatment of cancer are disclosed. The compositions in the form of a pill is administered to a human subject sequentially or alternately guided by the measurement of predictive biomarkers. | 2022-05-19 |
20220152076 | Injectable bifunctional hydrogel with antibacterial activity as well as the preparative method and the use thereof - An injectable bifunctional hydrogel has antibacterial activity. The bifunctional hydrogel is a hydrogel prepared by dissolving nucleoside analogues in a solvent. The nucleoside analog has a structure of formula I. It can be a candidate drug for the local injection treatment of periodontal disease, and it also has potential application prospects in the minimally invasive treatment of craniofacial bone tissue defects. | 2022-05-19 |
20220152077 | ADENOSINE RECEPTOR AGONISTS - The present invention relates to compounds of Formula (I) for use in the treatment of nervous system disorders and pain, wherein Formula (I) is: | 2022-05-19 |
20220152078 | 2'3'-CYCLIC DINUCLEOTIDES AND PRODRUGS THEREOF - The present disclosure relates to 2′3′ cyclic phosphonate dinucleotides of Formula (I), the pharmaceutically acceptable salts, pharmaceutical composition and combinations of the substances and other medicaments or pharmaceuticals. The disclosure also relates to the compounds for the treatment or prevention of diseases or conditions modifiable by STING protein modulation, such as cancer or viral, allergic and inflammatory diseases. | 2022-05-19 |
20220152079 | Methods For The Treatment Of APOC3-Related Diseases And Disorders - Described are methods for treating diseases and disorders that can be mediated in part by a reduction in APOC3 gene expression in a human subject in need of treatment, using pharmaceutical compositions that include APOC3 RNAi agents. The disclosed pharmaceutical compositions that include APOC3 RNAi agents, when administered to a human subject in need thereof according to the methods disclosed herein, treat diseases and disorders associated with elevated triglyceride (TG) levels, such as familial chylomicronemia syndrome (FCS), hypertriglyceridemia, obesity, dyslipidemia, non-alcoholic steatohepatitis, non-alcoholic fatty liver disease, hyperlipidemia, abnormal lipid and/or cholesterol metabolism, atherosclerosis, cardiovascular disease, coronary artery disease, hypertriglyceridemia induced pancreatitis, metabolic syndrome, type II diabetes mellitus, chylomicronemia, multifactorial chylomicronemia, or lipodystrophy syndromes including familial partial lipodystrophy. | 2022-05-19 |
20220152080 | RSK INHIBITORS IN THE TREATMENT OF VIRUS DISEASES - The present invention relates to RSK inhibitors that are capable of displaying one or more beneficial therapeutic effects. The RSK inhibitors can be used in the prevention and/or treatment of viral infection. RSK inhibitors alone or in combination with other anti-viral inhibitor compounds are capable of displaying one or more beneficial therapeutic effects in the treatment of viral diseases. | 2022-05-19 |
20220152081 | AGENTS AND METHODS FOR TREATING PANCREATIC DUCTAL ADENOCARCINOMAS - It has been discovered that NAD | 2022-05-19 |
20220152082 | Methods for Cancer Diagnosis, Prognosis or Treatment - The present invention is generally directed to a method for diagnosis, prognosis, or treatment of a cancer, by detecting or upregulating lncRNA, LINC00472. Particularly, LINC00472 is associated with the prognosis of ER-positive breast cancer and is involved in the interplay between ERα and NF-κB. | 2022-05-19 |
20220152083 | THERAPEUTIC TARGETS FOR FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY - The disclosure relates to methods and compositions for regulating expression of DUX4. In some aspects, methods described by the disclosure are useful for treating a disease associated with aberrant DUX4 expression (e.g., facioscapulohumeral muscular dystrophy). | 2022-05-19 |
20220152084 | PARTICLE-MEDIATED DELIVERY OF BIOLOGICS - A composition for delivering a biologic to a subject generally includes a particulate substrate and an mRNA encapsulated by the particulate substrate. In some cases, the mRNA bay be indirectly attached to the particulate substrate. The mRNA encodes at least one therapeutic polypeptide. The composition may be delivered to a tissue of a subject to provide a therapeutic benefit to the tissue. | 2022-05-19 |
20220152085 | COMBINATION IMMUNOREGULATION AND USES THEREOF - The present disclosure relates to compositions and methods for regulating the immune system and for treating cancers and other immune disorders. | 2022-05-19 |
20220152086 | METHODS FOR TREATING MUSCULAR DYSTROPHY WITH CASIMERSEN - The present disclosure provides, among other things, improved compositions and methods for treating muscular dystrophy. For example, the disclosure provides methods for treating Duchenne muscular dystrophy patients having a mutation in the DMD gene that is amenable to exon 45 skipping by administering an effective amount of casimersen. | 2022-05-19 |
20220152087 | CYCLODEXTRIN DERIVATIVES REDUCING FLAVIVIRUS NS1-INDUCED ENDOTHELIAL HYPERPERMEABILITY AND VASCULAR LEAK - The present invention generally relates to cyclodextrin derivatives, including Dexolve®, sulfobutylether beta cyclodextrin interfering with the activity of the viral nonstructural protein NS1 produced by a flavivirus. More particularly, the present invention relates to method of treatment using cyclodextrin compounds for inhibiting or treating a condition resulting from a flavivirus infection, particularly vascular leakage condition and increased virus dissemination. | 2022-05-19 |
20220152088 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS - Provided herein are pharmaceutical formulations and pharmaceutical compound salts which utilize complexing agents as counterions. Such formulations and salts are useful for treating a variety of disease and disorders. | 2022-05-19 |
20220152089 | COMPOSITION FOR THE PROTECTION AND REPAIR OF THE BLOOD BRAIN BARRIER - The present invention relates to a pharmaceutical composition for its application as a drug, in particular for use in the protection of the blood-brain barrier and/or the repair and/or the restoration of the blood brain barrier. The present invention finds an application in particular in the therapeutic, pharmaceutical and veterinary fields. | 2022-05-19 |
20220152090 | METHOD FOR TREATING AMYLOIDOGENIC DISEASE - The present disclosure relates to a method for treating or preventing or delaying the onset or progression of an amyloidogenic disease in a subject in need, comprising administering a pharmaceutical composition comprising a therapeutically effective amount of amphiphilic liposaccharide to the subject. The present disclosure also relates to a method for selecting an agent for treating or preventing or delaying the onset or progression of an amyloidogenic disease and a novel liposaccharide. | 2022-05-19 |
20220152091 | OXYGEN REACTIVE POLYMERS FOR TREATMENT OF TRAUMATIC BRAIN INJURY - Methods and compositions for treating traumatic brain injury. The methods and compositions utilize a multi-functional oxygen reactive polymer (ORP) that includes repeating units that include a reactive oxygen species (ROS) scavenging group and a polyalkylene oxide group. For theranostic applications, the oxygen reactive polymer further includes a diagnostic group. | 2022-05-19 |
20220152092 | MICROBIAL REMOVAL - Methoxy polyethylene glycol for use as a medicament, in particular in skin healing, wound healing and treatment of a microbial infection. A method for treating a medical device and/or implant to reduce or eliminate microbial contamination comprises applying a liquid formulation comprising methoxy polyethylene glycol. This invention relates to the novel discovery that methoxy polyethylene glycol, an inactive polymer with no known pharmacological effect, was able to come between microbes and a surface, removing the microbes or releasing the attachment or adherence of the microbes to the surface and thereby improving wound healing significantly, eliminating infections and colonies of microbes. | 2022-05-19 |
20220152093 | OPTIMIZED NUTRIENT SALT COMPOSITION - The invention relates to an optimized nutrient salt composition comprising elemental sodium and potassium in the ratio of 1:1.5 to 1:7 preferably 1:3 and elemental potassium to chloride in the ratio of 1:1 to 1:1.5 and method of preparing the same. Said composition can be optionally added with a) salts of calcium and, or magnesium as taste stabilizers, b) carbohydrate like polysaccharide, oligosaccharide, disaccharide, monosaccharide to produce energy electrolyte powder, c) food additives selected from anti-caking agents, crystal modifying agents, flavoring agents, flavor modifying agents, coloring agents and or any other food additives and d) nutrients selected from proteins, amino acids, carbohydrates, sugars, fat/oil, fatty acids, vitamins, minerals and water. Said optimized nutrient salt composition can be used as food, food ingredient, food supplement, table salt, preservative, food additive, seasoning agent and ingredient for oral rehydration fluid, intravenous fluids, beverages, energy drinks, sports/study drinks and stimulant drinks for humans, pets and livestock and for plant nutrition. | 2022-05-19 |
20220152094 | STABILIZED AMORPHOUS CALCIUM CARBONATE FOR TREATMENT OF NEUROLOGICAL, MUSCULAR AND INFERTILITY DISEASES OR CONDITIONS - Stabilized amorphous calcium carbonate (ACC) for treatment of several neurological, muscular and infertility diseases and conditions is provided. In particular, the stabilized ACC may be used in the treatment of axonal defects and muscular dystrophy. In addition, provided are improved methods used in assistant reproductive technology. Examples of such methods are in vitro fertilization and improvement of sperm quality. The improved IVF method, for example, comprises addition of the stabilized ACC to the cell culture medium in which the stages of fertilization and embryo development occurs. | 2022-05-19 |
20220152095 | ELECTROLYTE COMPOSITION AND METHODS OF USE - The present invention pertains to the field of oral electrolyte solutions (OES), particularly OES for calves. Particularly the present invention is in the fields of reducing diarrhea, reducing body weight loss, reducing fecal water loss and/or improving blood acid-base balance in a calf suffering from diarrhea. | 2022-05-19 |
20220152096 | IODINE COMPOSITIONS - The present invention relates to compositions comprising molecular iodine and a vehicle comprising a semifluorinated alkane. The compositions of the invention may be used to treat or prevent diseases or conditions caused by, or associated with microorganisms. | 2022-05-19 |
20220152097 | TREATMENT OF INFLAMMATORY BOWEL DISEASES THROUGH ADMINISTRATION OF ENTERIC AEROBIZATION THERAPY - Agents, kits, and methods that utilize oxygenation to treat Inflammatory Bowel Disease (IBD) and/or provide prophylaxis against exacerbation of IBD are provided. In several embodiments, the agents, kits, and methods according to several embodiments generate in, or carry to, oxygen in the intestinal lumen to treat IBD and provide prophylaxis against exacerbation of IBD, including those caused by the presence of anaerobic bacteria in the intestine. The agents, kits, and methods provided herein generate an aerobic environment within the intestine to alleviate intestinal inflammation. | 2022-05-19 |
20220152098 | METHODS OF MODULATING CD160 FUNCTION IN THE ANTIGEN-SPECIFIC IMMUNE CELL AND USES THEREOF - The present invention provides modified antigen-specific immune cells expressing an exogenous CD 160 protein. In some embodiments, the modified antigen-specific immune cell further comprises a functional exogenous receptor, such as an engineered TCR or a CAR. The present invention also provides methods of modulating CD 160 activity in antigen-specific immune cells. The present invention also provides methods and pharmaceutical compositions for cancer treatment using the modified antigen-specific immune cells and the modulators of CD 160 activity described herein. | 2022-05-19 |
20220152099 | Method for the preparation of an anti-streptococcus serum for use in the treatment of Coronavirus-related diseases. - An antistreptococcal serum for the treatment of respiratory and other diseases associated with Covid-19 and other Coronaviruses derived from the blood of a male foal of an ass less than 2 years old which has been prepared through successive incubations such as to render an otherwise fatal dose of streptococci innocuous. | 2022-05-19 |
20220152100 | METHODS FOR CONTROLLED ACTIVATION OR ELIMINATION OF THERAPEUTIC CELLS - The technology relates in part to methods for controlling the activity or elimination of therapeutic cells using multimerization of proteins to manipulate individual protein-protein interactions in therapeutic cells, for example, by activating or eliminating cells used to promote engraftment, to treat diseases or condition, or to control or modulate the activity of therapeutic cells that express chimeric antigen receptors or recombinant T cell receptors. | 2022-05-19 |
20220152101 | CELLULAR IMMUNOTHERAPY COMBINATION - Disclosed is a tumor treatment method, wherein immune effector cells and Gemcitabine are administered to an individual with tumor, and the immune effector cells express receptors having a tumor-specific antigen. Also disclosed is a tumor treatment kit, wherein the kit comprises 1) immune effector cells expressing receptors that recognize tumor antigens; 2) Gemcitabine; 3) a container for containing the substances of 1) and 2) described above; and 4) drug administration instructions for using the kit to treat a tumor. | 2022-05-19 |
20220152102 | EXPANSION OF NATURAL KILLER AND CHIMERIC ANTIGEN RECEPTOR-MODIFIED CELLS - Disclosed herein are methods and compositions for generating immunotherapeutic cells (e.g., NK and T cells) with enhanced cytotoxicity and capacity for expansion thereof. The methods and compositions disclosed herein can further be used for enhanced expansion of CAR-modified NK and T cells with increased cytotoxicity. | 2022-05-19 |
20220152103 | MUC1 PARALLEL CAR (pCAR) THERAPEUTIC AGENTS - Provided herein are immunoresponsive cells expressing a MUC1 targeting pCAR comprising a second generation chimeric antigen receptor (CAR) and a chimeric co-stimulatory receptor (CCR). Also provided herein are methods of preparing the immunoresponsive cells and methods of directing T cell mediated immune response using the immunoresponsive cells. | 2022-05-19 |
20220152104 | T CELL RECEPTORS AND METHODS OF USE THEREOF - The present disclosure is directed recombinant T cell receptors capable of binding an NY-ESO-1 epitope and nucleic acid molecules encoding the same. In some embodiments, the nucleic acid molecules further comprise a second nucleotide sequence, wherein the second nucleotide sequence or the polypeptide encoded by the second nucleotide sequence inhibits the expression of an endogenous TCR. Other aspects of the disclosure are directed to vectors comprising the nucleic acid molecule and cells comprising the recombinant TCR, the nucleic acid molecule, or the vector. Still other aspects of the disclosure are directed to methods of using the same. In some embodiments, the methods comprise treating a cancer in a subject in need thereof. | 2022-05-19 |
20220152105 | T CELL RECEPTORS AND METHODS OF USE THEREOF - The present disclosure is directed recombinant T cell receptors capable of binding an gp100 epitope and nucleic acid molecules encoding the same. In some embodiments, the nucleic acid molecules further comprise a second nucleotide sequence, wherein the second nucleotide sequence or the polypeptide encoded by the second nucleotide sequence inhibits the expression of an endogenous TCR. Other aspects of the disclosure are directed to vectors comprising the nucleic acid molecule and cells comprising the recombinant TCR, the nucleic acid molecule, or the vector. Still other aspects of the disclosure are directed to methods of using the same. In some embodiments, the methods comprise treating a cancer in a subject in need thereof. | 2022-05-19 |
20220152106 | CD147 CHIMERIC ANTIGEN RECEPTORS AND METHODS OF USE - Modified single chain variable fragments (scFv) that specifically bind CD147 are provided. Also provided are chimeric antigen receptors (CARs) including the modified CD147 scFv, nucleic acids encoding the CARs, vectors including the nucleic acids encoding the CARs, and immune cells expressing the CARs. Methods of treating a subject with cancer including administering to the subject an immune cell expressing a disclosed CD147-CAR are also provided. | 2022-05-19 |
20220152107 | METHOD FOR EXPANSION AND DIFFERENTIATION OF T LYMPHOCYTES AND NK CELLS FOR ADOPTIVE TRANSFER THERAPIES - The present invention describes a method for obtaining lymphoid cells having a desired phenotype for adoptive transfer therapies useful for the treatment of cancer. Especially, this invention is related to strategies for inducing preferential signaling through the intermediate affinity IL-2 receptor in order to expand the cells with a desired central memory phenotype. The method of the present invention is useful for obtaining tumor-infiltrating lymphocytes, TCR or chimeric antigen receptor engineered T cells for the treatment of cancer. | 2022-05-19 |
20220152108 | CHIMERIC ANTIGEN RECEPTORS DIRECTED TO CELLS EXPRESSING THE SODIUM TAUROCHOLATE CO-TRANSPORTING RECEPTOR - Aspects of the invention described herein relate to a chimeric antigen receptor (CAR), which can be presented on a cell or vesicle, which comprises the preS1 domain of the hepatitis B virus envelope protein and, which binds to cells expressing the sodium taurocholate co-transporting receptor (NTCP), such as NTCP expressing liver cells. Compositions comprising said CARs including cells and vesicles, methods of making said compositions, and methods of using said compositions to deliver a nucleic acid, protein, peptide, or drug, such as CRISPR/CAS system so as to treat, inhibit, or ameliorate a liver disease, such as liver cancer or pathogens infecting liver cells or to modulate a function of the liver cells are contemplated. | 2022-05-19 |
20220152109 | A2/NY-ESO-1 SPECIFIC T CELL RECEPTORS AND USES THEREOF - The application provides genetically modified cell receptors (TCRs) specific for an epitope from cancer antigen NY-ESO-1. Also provided are related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells, including but not limited to genetically engineered cells, and pharmaceutical compositions. The application further provides the use of such modified T cell receptors (TCRs) and related compositions for cancer immunotherapy (e.g., adoptive cell therapy). | 2022-05-19 |
20220152110 | Switchable Chimeric Antigen Receptor-Engineered Human Natural Killer Cells - Engineered natural killer cells with switchable chimeric antigen receptor, methods of manufacture, pharmaceutical compositions, and methods of use in treating cancer and viral infection. | 2022-05-19 |
20220152111 | PROCESS FOR T CELL EXPANSION - An in vitro expansion process for rapid expansion of antigen specific T cells, such as allogeneic antigen specific cells comprising the steps culturing in a gas permeable vessel a population of PBMCs (such as allogeneic PBMCs) in the presence of antigen, for example a peptide or peptide mix relevant to a target antigen(s), in the presence of an exogenous cytokine characterized in that the expansion to provide the desired population of T cells is 14 days or less, for example 9, 10, 11 or 12 days, such as 10 days. The disclosure also extends to T cell populations generated by and obtained from the method and the use of same in therapy. | 2022-05-19 |
20220152112 | NUCLEIC ACIDS ENCODING ENGINEERED MEGANUCLEASES WITH RECOGNITION SEQUENCES FOUND IN THE HUMAN T CELL RECEPTOR ALPHA CONSTANT REGION GENE - Disclosed herein are recombinant meganucleases engineered to recognize and cleave a recognition sequence present in the human T cell receptor alpha constant region gene. The present disclosure further relates to the use of such recombinant meganucleases in methods for producing genetically-modified eukaryotic cells. | 2022-05-19 |
20220152113 | METHODS FOR TREATING NON-CANCEROUS DISORDERS USING HEMATOPOIETIC CELLS - The invention provides methods of treating non-cancerous disorders in a subject by providing the subject with compositions containing hematopoietic cells. In certain embodiments, the compositions include CD34 | 2022-05-19 |
20220152114 | AUTOLOGOUS THYMIC TISSUE TRANSPLANTATION - The present disclosure provides methods and kits for preserving or restoring thymic functions of a subject in need thereof. The methods and kits disclosed herein include delivering an autologous thymic tissue into at least one lymph node of the subject. | 2022-05-19 |
20220152115 | MICROGLIAL PROGENITORS FOR REGENERATION OF FUNCTIONAL MICROGLIA IN THE CENTRAL NERVOUS SYSTEM AND THERAPEUTICS USES THEREOF - Embodiments of the disclosure include compositions and methods for treating diseases (e.g., brain diseases) using genetic engineered cells. In some cases, the cells are engineered hematopoietic stem cells (HSCs), which are capable of engrafting to a central nervous system and differentiating to progeny cells (e.g., microglial cells). | 2022-05-19 |
20220152116 | MULTI-STAGE PERSONALIZED LONGEVITY THERAPEUTICS - A method of treating senescence in a subject can include applying a senoremediation drug treatment protocol to the subject in order to rescue one or more first cells in the subject, wherein the senoremediation drug treatment protocol is derived from a computational transcriptome analysis of the tissue or organ of the subject. The method can include applying a senolytic drug treatment protocol to the subject in order to remove one or more second cells in the subject. The method can include introducing stem cells into a tissue and/or organ of the subject in order to rejuvenate one or more tissue cells in the tissue and/or one or more organ cells in the organ. The method can include carrying out a reinforcement step that includes one or more actions that prevent further senescence or degradation of the tissue or organ. | 2022-05-19 |
20220152117 | METHODS OF PROMOTING CELLULAR MATURATION WITH AMPK ACTIVATORS - Described herein are methods and compositions related to promoting maturation of in vitro-differentiated cardiomyocytes and in vitro-differentiated neurons, and methods and compositions using the resulting cardiomyocytes and neurons. | 2022-05-19 |
20220152118 | DIFFERENTIATION METHOD FROM HUMAN ADIPOSE-DERIVED MESENCHYMAL STEM CELLS TO DERMAL PAPILLA CELLS - The present invention relates to a method for differentiating from human adipose-derived mesenchymal stem cells to dermal papilla cells using a differentiation induction medium composition in a cell culture plate for inducing differentiation, including gelatin, and to the medium composition. The plate comprising the gelatin of the present invention can exhibit the effect of inducing direct cross-differentiation from human adipose-derived mesenchymal stem cells to dermal papilla cells, and the effect of efficiently enabling mass cultivation ex vivo at low cost by using an economical material. In addition, the dermal papilla cells differentiated from human adipose-derived mesenchymal stem cells of the present invention can be used as a cell therapy composition for preventing or treating hair loss. | 2022-05-19 |
20220152119 | COMPOSITIONS DERIVED FROM HUMAN AMNION CELLS & RELATED METHODS - A method for making an acellular human amnion-derived composition configured for therapeutic use is disclosed and generally includes the steps: obtaining amniotic membrane tissue; testing the amniotic membrane tissue for pathogens; washing the amniotic membrane tissue; manually removing blood-containing chorion tissue from the amniotic membrane tissue decellularizing the amniotic membrane tissue with xeno-free enzymes; collecting amniotic cells from the decellularized amniotic membrane tissue; seeding the amniotic cells for culture into xeno-free media formulated for mesenchymal stem cells; growing the amniotic cells to a specified confluency; collecting conditioned media; and freezing the collected conditioned media; wherein the method further includes irradiating the conditioned media. | 2022-05-19 |
20220152120 | BIRTH TISSUE-DERIVED PRODUCTS AND PREPARATION AND USES THEREOF - The present invention provides a composition for treating a pathological condition in a body part of a patient in needed thereof, comprising an effective amount of a birth tissue elute or birth tissue particulates. A method for preparing the birth tissue elute, for example, an umbilical cord elute, is also provided. A method for treating a pathological condition in a body part of a patient in needed thereof is further provided. | 2022-05-19 |
20220152121 | Composition and Use of Interleukin Stimulated Human Umbilical Cord Mesenchymal Stem Cells for the Treatment of Rheumatoid Arthritis - The present invention relates to a composition and method for treating rheumatoid arthritis, comprising interleukins (ILs), including IL-1β, stimulated human umbilical cord mesenchymal stem cells (hUCMSCs). The IL stimulated hUCMSCs of the present invention may induce the apoptosis of fibroblast-like synoviocytes rheumatoid arthritis (HFLS-RA) cells. IL stimulated hUCMSCs are useful to alleviate RA symptoms, such as inflammation, swelling and cartilage erosion, and exhibit therapeutic effects on rheumatoid arthritis. | 2022-05-19 |
20220152122 | METHOD OF TREATING MENINGIOMA - The present invention relates to a method of treating meningioma including administering a Chinese medicine composition to a subject in need thereof; wherein the Chinese medicine composition is an extract of a first mixture comprising | 2022-05-19 |
20220152123 | Treatment and prevention of neuropathology associated with neurodegenerative diseases - Administering a live, attenuated | 2022-05-19 |
20220152124 | APPLICATION OF A BILE ACID COMPOSITE BACTERIAL AGENT IN THE PREPARATION OF FEED ADDITIVES FOR MUTTON SHEEP - The present invention discloses application of a bile acid composite bacterial agent in the preparation of feed additives for mutton sheep. The bile acid composite bacterial agent comprises | 2022-05-19 |
20220152125 | SURGICAL RECOVERY SUPPLEMENT - A surgical recovery supplement is disclosed herein. One surgical recovery supplement includes one or more probiotics, one or more forms of fiber, and one or more collagens. Some surgical recovery supplements further include one or more minerals, one or more vitamins, one or more enzymes, one or more antioxidants, and/or one or more extracts. Methods for using the surgical recovery supplements are also disclosed herein. One method includes taking a three times dose of a surgical supplement once a day for 30 days. Another method includes taking a single dose of a surgical supplement three times a day for 30 days. | 2022-05-19 |
20220152126 | LACTOCOCCUS LACTIS STRAINS FOR THE PREVENTION AND/OR THE TREATMENT OF VISCERAL PAIN | 2022-05-19 |
20220152127 | ENGINEERED LACTOCOCCUS - The present invention refers to a microorganism characterized in that it is genetically modified to express the human growth factor of keratinocytes (KGF/FGF7) or its functional orthologues, derivatives or fragments. | 2022-05-19 |
20220152128 | BEE GUT MICROBIAL FORMULATION FOR USE AS A PROBIOTIC FOR IMPROVED BEE HEALTH AND PATHOGEN RESISTANCE - Provided herein are defined bacterial co-cultures, and methods of generating the same. Further provided are methods of using the defined bacterial co-cultures as probiotics to prevent diseases or disorders in bees and bee colonies. | 2022-05-19 |
20220152129 | EXTERNAL COMPOSITION FOR WOUND HEALING CONTAINING LACTOBACILLUS FERMENTATION PRODUCT AND METHOD FOR PROMOTING WOUND HEALING USING THE SAME - The present disclosure relates to as external composition for wound healing containing a | 2022-05-19 |
20220152130 | Multifunctional lactobacillus capable of relieving pfoa toxic effects and application thereof - The present disclosure discloses multifunctional lactobacilli capable of relieving a toxic effect of perfluorooctanoic acid (PFOA) and use thereof, and belongs to the technical field of microorganisms. | 2022-05-19 |
20220152131 | BACTERIOPHAGE TREATMENT AND REDUCTION IN INFLAMMATORY RESPONSE - The present invention relates to the treatment of bacterial infections and the reduction of inflammatory response using bacteriophage compositions. In an aspect, provided herein are methods of treating a bacterial infection characterized by inflammation in a subject, the method comprising administering to the subject a bacteriophage composition that is essentially free of impurities, wherein the composition reduces inflammation. | 2022-05-19 |